Change of cfPWV and progression of arterial stiffness after 12 and 24 weeks of oral MK-7 supplementation, Change of biochemistry parameters, vascular and bone turnover markers in blood after 12 and 24 weeks of oral MK-7 treatment, Incidence of side effects, thrombotic events and death from MK-7 supplement Menaquinone-7, Arterial stiffness, Carotid-femoral pulse wave velocity, Chronic hemodialysis
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Age equal or more than 18 years at screening Undergoing maintenance HD at least 2 times a week for more than 1 month prior to screening and compliance with HD treatments cfPWV measurement equal or more than 10 m/s at screening visit
Exclusion criteria
Exclusion criteria: Pregnancy and breastfeeding Receiving vitamin K antagonist or warfarin Receiving and/or history of vitamin K supplementation in 3 months before screening History of percutaneous coronary intervention and/or coronary artery bypass grafting Patients with conditions that were unable to assess cfPWV including deformity of peripheral limbs, amputation, and severe peripheral vascular disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| cPWV change 24 weeks Carotid-femoral pulse wave velocity | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in blood sugar, HbA1C 24 weeks laboratory chemistry,Change in cholesterol 24 weeks laboratory chemistry,Change in iPTH, vitamin D (25-OH vitamin D) 24 weeks laboratory chemistry,Change in serum calcium, phosphate and albumin 24 weeks laboratory chemistry,Aortic calcification score 24 weeks abdominal lateral x-ray | — |
Countries
Thailand
Contacts
Faculty of Medicine, Chulalongkorn University